1. ROR1-targeted adoptive immunotherapies
- Author
-
Harrasser, Micaela
- Subjects
616.99 - Abstract
The tumour antigen ROR1 plays a critical role in tumorigenesis and is overexpressed in several haematological and solid malignancies including triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). Its absence on most of healthy tissues makes it an attractive target for cancer immunotherapy. Cancer immunotherapy has opened a new era of cancer treatments. Successful examples include therapeutic antibodies (e.g. Rituximab, and immune checkpoint inhibitors) and adoptive cell therapy with engineered T cells expressing a Chimeric Antigen Receptor (CAR), particularly against haematological malignancies. CAR-T cells have so far had limited success against solid tumours. Overexpression of inhibitory receptor ligands such as PD-L1 by tumour cells is one of the main mechanisms that makes the anti-tumour immune response ineffective. We developed a second generation ROR1-41BB-CD3ζ CAR targeting ROR1. These CAR-T cells rapidly acquired a phenotype associated with increased expression of programmed death receptor 1 (PD-1) following exposure to ROR1-expressing tumour targets. To bolsters potency, we engineered the lentiviral CAR construct to enable IL-2 mediated, NFAT-induced secretion of anti-PD-1 single-chain variable fragments (scFv) within the tumour environment following CAR T-cell activation. Local secretion of anti-PD1 scFv led to increased anti-tumour activity against TNBC and NSCLC tumour cell lines in in vitro co-culture studies. In a murine xenograft model of TNBC, tumour growth was significantly decreased and associated with a significant survival benefit compared to parental ROR1 CAR-T cells and to combination therapy with ROR1 CAR-T cells and anti-PD1 monoclonal antibody. Thus, second-generation CAR T cells engineered to secrete anti-PD-1 scFv shows promise and represents a clinically relevant approach to improving potency of CAR-T cells against solid tumours whilst limiting toxicities associated with systemic administration of monoclonal antibody-mediated checkpoint inhibition.
- Published
- 2020